Anavex Life Sciences Corp.
AVXL
$4.31
-$0.27-5.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.13% | 71.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.43% | 15.42% | |||
| Operating Income | 24.43% | -15.42% | |||
| Income Before Tax | 25.79% | -18.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.79% | -18.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.79% | -18.28% | |||
| EBIT | 24.43% | -15.42% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 26.24% | -17.86% | |||
| Normalized Basic EPS | 26.21% | -17.74% | |||
| EPS Diluted | 26.24% | -17.86% | |||
| Normalized Diluted EPS | 26.21% | -17.74% | |||
| Average Basic Shares Outstanding | 0.60% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.60% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||